CDX-2 homeobox gene product expression in neuroendocrine tumors: Its role as a marker of intestinal neuroendocrine tumors

Mattia Barbareschi, Claudia Roldo, Giuseppe Zamboni, Paola Capelli, Alberto Cavazza, Ettore Macri, M. Giulia Cangi, Marco Chilosi, Claudio Doglioni

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

CDX-2 is a homeobox gene product essential for intestinal development and differentiation. It can be used as a specific marker of colorectal adenocarcinomas and other tumors with intestinal differentiation, but little is known about its expression in endocrine and neuroendocrine (NE) cells and NE primary and metastatic tumors. Using the Cdx-2-88 monoclonal antibody, we evaluated CDX-2 expression in routine samples of 20 normal endocrine/NE tissues and of 299 samples of well-differentiated NE tumors (WDNET) and high-grade NE carcinomas (NEC) from different sites. For 17 cases, we examined primary and corresponding metastatic lesions. We also examined 8 cytologic samples of liver metastases derived from 4 ileal WDNETs, 1 lung WDNET, and 3 pancreatic endocrine tumors. CDX-2 mRNA expression with RT-PCR technique on frozen material was evaluated in 5 WDNETs. CDX-2 was expressed in normal NE cells of the intestine and gastric fundus. High CDX-2 expression was seen in all ileal and appendiceal WDNET, while low levels were seen in WDNETs from stomach, duodenum, and rectum; no reactivity was seen in other WDNETs. Low levels of CDX-2 expression were seen in one third of nonfunctioning pancreatic WDNET where it was more frequently observed in cases with metastatic disease (P = 0.002). CDX-2 was identified in all cytologic specimens of metastatic ileal WDNETs. CDX-2 mRNA analysis confirmed immunohistochemical results. CDX-2 was expressed at high levels in 81% of intestinal NEC. Unexpectedly, variable levels of expression of CDX-2 were seen also in 39% of NEC of other sites, without any relation with the site of origin. This reactivity frequently overlapped TTF-1 expression, suggesting deregulated expression of homeobox genes in NEC. The restricted pattern of CDX-2 expression may have diagnostic value in the identification of the primary site of a metastatic WDNET. Conversely, a limited diagnostic role is suggested for CDX-2 in NEC because of its frequent expression in nongastrointestinal tumors.

Original languageEnglish
Pages (from-to)1169-1176
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume28
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Neuroendocrine Tumors
Homeobox Genes
Gene Expression
Neoplasms
Carcinoma
Neuroendocrine Cells
Gastric Fundus
Neuroendocrine Carcinoma
Messenger RNA
Endocrine Cells
Duodenum
Rectum
Intestines
Stomach
Adenocarcinoma
Monoclonal Antibodies
Neoplasm Metastasis
Polymerase Chain Reaction
Lung
Liver

Keywords

  • CDX-2
  • Diagnostic marker
  • Human neoplasms
  • Immunohistochemistry
  • Neuroendocrine

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

CDX-2 homeobox gene product expression in neuroendocrine tumors : Its role as a marker of intestinal neuroendocrine tumors. / Barbareschi, Mattia; Roldo, Claudia; Zamboni, Giuseppe; Capelli, Paola; Cavazza, Alberto; Macri, Ettore; Cangi, M. Giulia; Chilosi, Marco; Doglioni, Claudio.

In: American Journal of Surgical Pathology, Vol. 28, No. 9, 09.2004, p. 1169-1176.

Research output: Contribution to journalArticle

Barbareschi, Mattia ; Roldo, Claudia ; Zamboni, Giuseppe ; Capelli, Paola ; Cavazza, Alberto ; Macri, Ettore ; Cangi, M. Giulia ; Chilosi, Marco ; Doglioni, Claudio. / CDX-2 homeobox gene product expression in neuroendocrine tumors : Its role as a marker of intestinal neuroendocrine tumors. In: American Journal of Surgical Pathology. 2004 ; Vol. 28, No. 9. pp. 1169-1176.
@article{db466e8f73a347e7a7e84b1f2a4a0557,
title = "CDX-2 homeobox gene product expression in neuroendocrine tumors: Its role as a marker of intestinal neuroendocrine tumors",
abstract = "CDX-2 is a homeobox gene product essential for intestinal development and differentiation. It can be used as a specific marker of colorectal adenocarcinomas and other tumors with intestinal differentiation, but little is known about its expression in endocrine and neuroendocrine (NE) cells and NE primary and metastatic tumors. Using the Cdx-2-88 monoclonal antibody, we evaluated CDX-2 expression in routine samples of 20 normal endocrine/NE tissues and of 299 samples of well-differentiated NE tumors (WDNET) and high-grade NE carcinomas (NEC) from different sites. For 17 cases, we examined primary and corresponding metastatic lesions. We also examined 8 cytologic samples of liver metastases derived from 4 ileal WDNETs, 1 lung WDNET, and 3 pancreatic endocrine tumors. CDX-2 mRNA expression with RT-PCR technique on frozen material was evaluated in 5 WDNETs. CDX-2 was expressed in normal NE cells of the intestine and gastric fundus. High CDX-2 expression was seen in all ileal and appendiceal WDNET, while low levels were seen in WDNETs from stomach, duodenum, and rectum; no reactivity was seen in other WDNETs. Low levels of CDX-2 expression were seen in one third of nonfunctioning pancreatic WDNET where it was more frequently observed in cases with metastatic disease (P = 0.002). CDX-2 was identified in all cytologic specimens of metastatic ileal WDNETs. CDX-2 mRNA analysis confirmed immunohistochemical results. CDX-2 was expressed at high levels in 81{\%} of intestinal NEC. Unexpectedly, variable levels of expression of CDX-2 were seen also in 39{\%} of NEC of other sites, without any relation with the site of origin. This reactivity frequently overlapped TTF-1 expression, suggesting deregulated expression of homeobox genes in NEC. The restricted pattern of CDX-2 expression may have diagnostic value in the identification of the primary site of a metastatic WDNET. Conversely, a limited diagnostic role is suggested for CDX-2 in NEC because of its frequent expression in nongastrointestinal tumors.",
keywords = "CDX-2, Diagnostic marker, Human neoplasms, Immunohistochemistry, Neuroendocrine",
author = "Mattia Barbareschi and Claudia Roldo and Giuseppe Zamboni and Paola Capelli and Alberto Cavazza and Ettore Macri and Cangi, {M. Giulia} and Marco Chilosi and Claudio Doglioni",
year = "2004",
month = "9",
doi = "10.1097/01.pas.0000131531.75602.b9",
language = "English",
volume = "28",
pages = "1169--1176",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - CDX-2 homeobox gene product expression in neuroendocrine tumors

T2 - Its role as a marker of intestinal neuroendocrine tumors

AU - Barbareschi, Mattia

AU - Roldo, Claudia

AU - Zamboni, Giuseppe

AU - Capelli, Paola

AU - Cavazza, Alberto

AU - Macri, Ettore

AU - Cangi, M. Giulia

AU - Chilosi, Marco

AU - Doglioni, Claudio

PY - 2004/9

Y1 - 2004/9

N2 - CDX-2 is a homeobox gene product essential for intestinal development and differentiation. It can be used as a specific marker of colorectal adenocarcinomas and other tumors with intestinal differentiation, but little is known about its expression in endocrine and neuroendocrine (NE) cells and NE primary and metastatic tumors. Using the Cdx-2-88 monoclonal antibody, we evaluated CDX-2 expression in routine samples of 20 normal endocrine/NE tissues and of 299 samples of well-differentiated NE tumors (WDNET) and high-grade NE carcinomas (NEC) from different sites. For 17 cases, we examined primary and corresponding metastatic lesions. We also examined 8 cytologic samples of liver metastases derived from 4 ileal WDNETs, 1 lung WDNET, and 3 pancreatic endocrine tumors. CDX-2 mRNA expression with RT-PCR technique on frozen material was evaluated in 5 WDNETs. CDX-2 was expressed in normal NE cells of the intestine and gastric fundus. High CDX-2 expression was seen in all ileal and appendiceal WDNET, while low levels were seen in WDNETs from stomach, duodenum, and rectum; no reactivity was seen in other WDNETs. Low levels of CDX-2 expression were seen in one third of nonfunctioning pancreatic WDNET where it was more frequently observed in cases with metastatic disease (P = 0.002). CDX-2 was identified in all cytologic specimens of metastatic ileal WDNETs. CDX-2 mRNA analysis confirmed immunohistochemical results. CDX-2 was expressed at high levels in 81% of intestinal NEC. Unexpectedly, variable levels of expression of CDX-2 were seen also in 39% of NEC of other sites, without any relation with the site of origin. This reactivity frequently overlapped TTF-1 expression, suggesting deregulated expression of homeobox genes in NEC. The restricted pattern of CDX-2 expression may have diagnostic value in the identification of the primary site of a metastatic WDNET. Conversely, a limited diagnostic role is suggested for CDX-2 in NEC because of its frequent expression in nongastrointestinal tumors.

AB - CDX-2 is a homeobox gene product essential for intestinal development and differentiation. It can be used as a specific marker of colorectal adenocarcinomas and other tumors with intestinal differentiation, but little is known about its expression in endocrine and neuroendocrine (NE) cells and NE primary and metastatic tumors. Using the Cdx-2-88 monoclonal antibody, we evaluated CDX-2 expression in routine samples of 20 normal endocrine/NE tissues and of 299 samples of well-differentiated NE tumors (WDNET) and high-grade NE carcinomas (NEC) from different sites. For 17 cases, we examined primary and corresponding metastatic lesions. We also examined 8 cytologic samples of liver metastases derived from 4 ileal WDNETs, 1 lung WDNET, and 3 pancreatic endocrine tumors. CDX-2 mRNA expression with RT-PCR technique on frozen material was evaluated in 5 WDNETs. CDX-2 was expressed in normal NE cells of the intestine and gastric fundus. High CDX-2 expression was seen in all ileal and appendiceal WDNET, while low levels were seen in WDNETs from stomach, duodenum, and rectum; no reactivity was seen in other WDNETs. Low levels of CDX-2 expression were seen in one third of nonfunctioning pancreatic WDNET where it was more frequently observed in cases with metastatic disease (P = 0.002). CDX-2 was identified in all cytologic specimens of metastatic ileal WDNETs. CDX-2 mRNA analysis confirmed immunohistochemical results. CDX-2 was expressed at high levels in 81% of intestinal NEC. Unexpectedly, variable levels of expression of CDX-2 were seen also in 39% of NEC of other sites, without any relation with the site of origin. This reactivity frequently overlapped TTF-1 expression, suggesting deregulated expression of homeobox genes in NEC. The restricted pattern of CDX-2 expression may have diagnostic value in the identification of the primary site of a metastatic WDNET. Conversely, a limited diagnostic role is suggested for CDX-2 in NEC because of its frequent expression in nongastrointestinal tumors.

KW - CDX-2

KW - Diagnostic marker

KW - Human neoplasms

KW - Immunohistochemistry

KW - Neuroendocrine

UR - http://www.scopus.com/inward/record.url?scp=4344644561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344644561&partnerID=8YFLogxK

U2 - 10.1097/01.pas.0000131531.75602.b9

DO - 10.1097/01.pas.0000131531.75602.b9

M3 - Article

C2 - 15316316

AN - SCOPUS:4344644561

VL - 28

SP - 1169

EP - 1176

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 9

ER -